Fentanyl Transdermal

Name: Fentanyl Transdermal

Uses

This medication is used to help relieve moderate to severe ongoing pain (such as due to cancer). Fentanyl belongs to a class of drugs known as narcotic (opiate) analgesics. It works in the brain to change how your body feels and responds to pain.

Clinical pharmacology

Mechanism Of Action

Fentanyl is an opioid analgesic. Fentanyl interacts predominately with the opioid mu-receptor. These mu-binding sites are distributed in the human brain, spinal cord, and other tissues.

Pharmacodynamics

Central Nervous System Effects

Fentanyl exerts its principal pharmacologic effects on the central nervous system. Central nervous system effects increase with increasing serum fentanyl concentrations.

In addition to analgesia, alterations in mood, euphoria, dysphoria, and drowsiness commonly occur. Fentanyl depresses the respiratory centers, depresses the cough reflex, and constricts the pupils. Analgesic blood concentrations of fentanyl may cause nausea and vomiting directly by stimulating the chemoreceptor trigger zone, but nausea and vomiting are significantly more common in ambulatory than in recumbent patients, as is postural syncope.

Ventilatory Effects

In clinical trials of 357 non-opioid tolerant subjects treated with DURAGESIC, 13 subjects experienced hypoventilation. Hypoventilation was manifested by respiratory rates of less than 8 breaths/minute or a pCO2 greater than 55 mm Hg. In these studies, the incidence of hypoventilation was higher in nontolerant women (10) than in men (3) and in subjects weighing less than 63 kg (9 of 13). Although subjects with prior impaired respiration were not common in the trials, they had higher rates of hypoventilation. In addition, post-marketing reports have been received that describe opioid-naive post-operative patients who have experienced clinically significant hypoventilation and death with DURAGESIC.

Hypoventilation can occur throughout the therapeutic range of fentanyl serum concentrations, especially for patients who have an underlying pulmonary condition or who receive concomitant opioids or other CNS drugs associated with hypoventilation. The use of DURAGESIC is contraindicated in patients who are not tolerant to opioid therapy.

Gastrointestinal Tract And Other Smooth Muscle

Opioids increase the tone and decrease the propulsive contractions of the smooth muscle of the gastrointestinal tract. The resultant prolongation in gastrointestinal transit time may be responsible for the constipating effect of fentanyl. Because opioids may increase biliary tract pressure, some patients with biliary colic may experience worsening rather than relief of pain.

While opioids generally increase the tone of urinary tract smooth muscle, the net effect tends to be variable, in some cases producing urinary urgency, in others, difficulty in urination.

Cardiovascular Effects

Fentanyl may cause orthostatic hypotension and fainting. Fentanyl may infrequently produce bradycardia. The incidence of bradycardia in clinical trials with DURAGESIC was less than 1%.

Histamine assays and skin wheal testing in clinical studies indicate that clinically significant histamine release rarely occurs with fentanyl administration. Clinical assays show no clinically significant histamine release in dosages up to 50 mcg/kg.

Pharmacokinetics

Absorption

DURAGESIC is a drug-in-adhesive matrix designed formulation. Fentanyl is released from the matrix at a nearly constant amount per unit time. The concentration gradient existing between the matrix and the lower concentration in the skin drives drug release. Fentanyl moves in the direction of the lower concentration at a rate determined by the matrix and the diffusion of fentanyl through the skin layers. While the actual rate of fentanyl delivery to the skin varies over the 72-hour application period, each system is labeled with a nominal flux which represents the average amount of drug delivered to the systemic circulation per hour across average skin.

While there is variation in dose delivered among patients, the nominal flux of the systems (12.5, 25, 50, 75, and 100 mcg of fentanyl per hour) is sufficiently accurate as to allow individual titration of dosage for a given patient.

Following DURAGESIC application, the skin under the system absorbs fentanyl, and a depot of fentanyl concentrates in the upper skin layers. Fentanyl then becomes available to the systemic circulation. Serum fentanyl concentrations increase gradually following initial DURAGESIC application, generally leveling off between 12 and 24 hours and remaining relatively constant, with some fluctuation, for the remainder of the 72-hour application period. Peak serum concentrations of fentanyl generally occurred between 20 and 72 hours after initial application (see Table 6). Serum fentanyl concentrations achieved are proportional to the DURAGESIC delivery rate. With continuous use, serum fentanyl concentrations continue to rise for the first two system applications. By the end of the second 72-hour application, a steady-state serum concentration is reached and is maintained during subsequent applications of a patch of the same size (see Figure 1). Patients reach and maintain a steady-state serum concentration that is determined by individual variation in skin permeability and body clearance of fentanyl.

After system removal, serum fentanyl concentrations decline gradually, falling about 50% in approximately 20–27 hours. Continued absorption of fentanyl from the skin accounts for a slower disappearance of the drug from the serum than is seen after an IV infusion, where the apparent half-life is approximately 7 (range 3–12) hours.

A clinical pharmacology study conducted in healthy adult subjects has shown that the application of heat over the DURAGESIC system increased mean overall fentanyl exposure by 120% and average maximum fentanyl level by 61%.

Table 6: FENTANYL PHARMACOKINETIC PARAMETERS FOLLOWING FIRST 72-HOUR APPLICATION OF DURAGESIC

  Mean (SD) Time to Maximal Concentration Tmax (h) Mean (SD) Maximal Concentration Cmax (ng/mL)
DURAGESIC 12 mcg/h 28.8 (13.7) 0.38 (0.13)*
DURAGESIC 25 mcg/h 31.7 (16.5) 0.85 (0.26)**
DURAGESIC 50 mcg/h 32.8 (15.6) 1.72 (0.53)**
DURAGESIC 75 mcg/h 35.8 (14.1) 2.32 (0.86)**
DURAGESIC 100 mcg/h 29.9 (13.3) 3.36 (1.28)**
*Cmax values dose normalized from 4 × 12.5 mcg/h: Study 2003-038 in healthy volunteers
**Cmax values: Study C-2002-048 dose proportionality study in healthy volunteers
NOTE: After system removal there is continued systemic absorption from residual fentanyl in the skin so that serum concentrations fall 50%, on average, in approximately 20-27 hours.

Figure 1 : Serum Fentanyl Concentrations Following Single and Multiple Applications of DURAGESIC 100 mcg/h

Table 7: RANGE OF PHARMACOKINETIC PARAMETERS OF INTRAVENOUS FENTANYL IN PATIENTS

  Clearance (L/h) Range [70 kg] Volume of Distribution Vss (L/kg) Range Half-Life t½ (h) Range
Surgical Patients 27-75 3-8 3-12
Hepatically Impaired 3-80+ 0.8-8+ 4-12+
Patients      
Renally Impaired Patients 30-78 - -
+Estimated
NOTE: Information on volume of distribution and half-life not available for renally impaired patients.

Distribution

Fentanyl plasma protein binding capacity decreases with increasing ionization of the drug. Alterations in pH may affect its distribution between plasma and the central nervous system. Fentanyl accumulates in the skeletal muscle and fat and is released slowly into the blood. The average volume of distribution for fentanyl is 6 L/kg (range 3-8; N=8).

Metabolism

Fentanyl is metabolized primarily via human cytochrome P450 3A4 isoenzyme system. In humans, the drug appears to be metabolized primarily by oxidative N-dealkylation to norfentanyl and other inactive metabolites that do not contribute materially to the observed activity of the drug.

Excretion

Within 72 hours of IV fentanyl administration, approximately 75% of the dose is excreted in urine, mostly as metabolites with less than 10% representing unchanged drug. Approximately 9% of the dose is recovered in the feces, primarily as metabolites. Mean values for unbound fractions of fentanyl in plasma are estimated to be between 13 and 21%.

Skin does not appear to metabolize fentanyl delivered transdermally. This was determined in a human keratinocyte cell assay and in clinical studies in which 92% of the dose delivered from the system was accounted for as unchanged fentanyl that appeared in the systemic circulation.

Specific Populations

Geriatric Use

Data from intravenous studies with fentanyl suggest that the elderly patients may have reduced clearance and a prolonged half-life. Moreover elderly patients may be more sensitive to the active substance than younger patients. A study conducted with the DURAGESIC fentanyl transdermal patch in elderly patients demonstrated that fentanyl pharmacokinetics did not differ significantly from young adult subjects, although peak serum concentrations tended to be lower and mean half-life values were prolonged to approximately 34 hours. In this study, a single DURAGESIC 100 μg/hour patch was applied to a skin site on the upper outer arm in a group of healthy elderly Caucasians ≥ 65 years old (n=21, mean age 71 years) and worn for 72 hours. The mean Cmax and AUC∞ values were approximately 8% lower and 7% higher, respectively, in the elderly subjects as compared with subjects 18 to 45 years old. Inter-subject variability in AUC∞ was higher in elderly subjects than in healthy adult subjects 18 to 45 years (58% and 37%, respectively). The mean half-life value was longer in subjects ≥ 65 years old than in subjects 18 to 45 years old (34.4 hours versus 23.5 hours) [see WARNINGS AND PRECAUTIONS and Use In Specific Populations].

Pediatric Use

In 1.5 to 5 year old, non-opioid-tolerant pediatric patients, the fentanyl plasma concentrations were approximately twice as high as that of adult patients. In older pediatric patients, the pharmacokinetic parameters were similar to that of adults. However, these findings have been taken into consideration in determining the dosing recommendations for opioid-tolerant pediatric patients (2 years of age and older). For pediatric dosing information, refer to [see DOSING AND ADMINISTRATION].

Hepatic Impairment

Information on the effect of hepatic impairment on the pharmacokinetics of DURAGESIC is limited. The pharmacokinetics of DURAGESIC delivering 50 μg/hour of fentanyl for 72 hours was evaluated in patients hospitalized for surgery. Compared to the controlled patients (n=8), Cmax and AUC in the patients with cirrhosis (n=9) increased 35% and 73%, respectively.

Because there is in-vitro and in-vivo evidence of extensive hepatic contribution to the elimination of DURAGESIC, hepatic impairment would be expected to have significant effects on the pharmacokinetics of DURAGESIC. Avoid use of DURAGESIC in patients with severe hepatic impairment [see DOSING AND ADMINISTRATION, WARNINGS AND PRECAUTIONS, and Use in Specific Populations].

Renal Impairment

Information on the effect of renal impairment on the pharmacokinetics of DURAGESIC is limited. The pharmacokinetics of intravenous injection of 25 μg/kg fentanyl was evaluated in patients (n=8) undergoing kidney transplantation. An inverse relationship between blood urea nitrogen level and fentanyl clearance was found. Because there is in-vivo evidence of renal contribution to the elimination of DURAGESIC, renal impairment would be expected to have significant effects on the pharmacokinetics of DURAGESIC. Avoid the use of DURAGESIC in patients with severe renal impairment [see DOSING AND ADMINISTRATION, WARNINGS AND PRECAUTIONS and Use In Specific Populations].

Drug-Drug Interactions

CYP3A4 Inhibitors

Fentanyl is metabolized mainly via the human cytochrome P450 3A4 isoenzyme system (CYP3A4). The interaction between ritonavir, a CPY3A4 inhibitor, and fentanyl was investigated in eleven healthy volunteers in a randomized crossover study. Subjects received oral ritonavir or placebo for 3 days. The ritonavir dose was 200 mg tid on Day 1 and 300 mg tid on Day 2 followed by one morning dose of 300 mg on Day 3. On Day 2, fentanyl was given as a single IV dose at 5 mcg/kg two hours after the afternoon dose of oral ritonavir or placebo. Naloxone was administered to counteract the side effects of fentanyl. The results suggested that ritonavir might decrease the clearance of fentanyl by 67%, resulting in a 174% (range 52%– 420%) increase in fentanyl AUC0-∞. The concomitant use of transdermal fentanyl with all CYP3A4 inhibitors (such as ritonavir, ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, nefazadone, amiodarone, amprenavir, aprepitant, diltiazem, erythromycin, fluconazole, fosamprenavir, verapamil, or grapefruit juice) may result in an increase in fentanyl plasma concentrations, which could increase or prolong adverse drug effects and may cause potentially fatal respiratory depression. Carefully monitor patients receiving DURAGESIC and any CYP3A4 inhibitor for signs of respiratory depression for an extended period of time and adjust the dosage if warranted [see BOXED WARNING and WARNINGS AND PRECAUTIONS, and DRUG INTERACTIONS].

CYP3A4 Inducers

Co-administration with agents that induce CYP3A4 activity may reduce the efficacy of DURAGESIC.

Clinical Studies

DURAGESIC as therapy for pain due to cancer has been studied in 153 patients. In this patient population, DURAGESIC has been administered in doses of 25 μg/h to 600 μg/h. Individual patients have used DURAGESIC continuously for up to 866 days. At one month after initiation of DURAGESIC therapy, patients generally reported lower pain intensity scores as compared to a prestudy analgesic regimen of oral morphine.

The duration of DURAGESIC use varied in cancer patients; 56% of patients used DURAGESIC for over 30 days, 28% continued treatment for more than 4 months, and 10% used DURAGESIC for more than 1 year.

In the pediatric population, the safety of DURAGESIC has been evaluated in 289 patients with chronic pain 2–18 years of age. The duration of DURAGESIC use varied; 20% of pediatric patients were treated for ≤ 15 days; 46% for 16–30 days; 16% for 31–60 days; and 17% for at least 61 days. Twenty-five patients were treated with DURAGESIC for at least 4 months and 9 patients for more than 9 months.

Dosing & Uses

Dosage Forms & Strengths

transdermal patch: Schedule II

  • 12.5mcg/hr
  • 25mcg/hr
  • 50mcg/hr
  • 75mcg/hr
  • 100mcg/hr

Chronic Severe Pain

Indicated for chronic pain in opioid-tolerant patients, severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate

25-100 mcg/hr, reapplied q72hr until adequate analgesia is achieved

Refer to opioid conversion table in prescribing information

Opioid-tolerant definition

  • Patients who are opioid tolerant are those receiving, for 1 week or longer, at least 60 mg/day PO morphine, 30 mg/day PO oxycodone, 8 mg/day PO hydromorphone, 25 mg/day PO oxymorphone, or an equianalgesic dose of another opioid

Limitations of use

  • Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, and because of the greater risks of overdose and death with extended-release opioid formulations, reserve for patients whom alternative treatment options (eg, nonopioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain

Dosing Considerations

Not for use in acute pain or as PRN analgesic

Conversion to transdermal patch: Estimate daily PO morphine equivalent, then decrease by 25-50% to select initial patch; also supply PO opioid for breakthrough pain during transition to patch and titration

Discontinue all other around-the-clock opioid drugs when initiating the fentanyl patch

Initial dose may be approximated from the 24 hr morphine dosage equivalent; titrate to minimize effects; replace patch every 3 days

Patients with adequate relief with a fentanyl infusion may be converted  to transdermal dosing at a rate equivalent to intravenous rate

Dosage should not be titrated more frequently than 3 days after the initial dose or every 6 days thereafter; patient should wear a consistent fentanyl dosage patch through two applications (6 days) before dosage increase based on supplemental opioid dosages can be estimated

Most patients may be controlled on every 72 hr administration; a minority of patients may require every 48hr administration

Dosage Forms & Strengths

transdermal patch: Schedule II

  • 12.5mcg/hr
  • 25mcg/hr
  • 50mcg/hr
  • 75mcg/hr
  • 100mcg/hr

Chronic Pain (Off-label)

Treatment of chronic pain in children who are opioid-tolerant and receiving ≥60 mg/day PO of morphine or equivalent

<2 years: Safety not established

≥2 years: 25-100 mcg/hr, reapplied q72hr until adequate analgesia is achieved

Dosing considerations

  • Not for use in acute pain or as PRN analgesic
  • Conversion to transdermal patch: Estimate daily PO morphine equivalent, then decrease by 25-50% to select initial patch; also supply PO opioid for breakthrough pain during transition to patch and titration
  • Discontinue all other around-the-clock opioid drugs when initiating the fentanyl patch
  • Initial dose may be approximated from the 24 hr morphine dosage equivalent; titrate to minimize effects; replace patch every 3 days
  • Patients with adequate relief with a fentanyl infusion may be converted to transdermal dosing at a rate equivalent to intravenous rate
  • Dosage should not be titrated more frequently than 3 days after the initial dose or every 6 days thereafter; patient should wear a consistent fentanyl dosage patch through two applications (6 days) before dosage increase based on supplemental opioid dosages can be estimated
  • Most patients may be controlled on every 72 hr administration; a minority of patients may require every 48hr administration

Pharmacology

Mechanism of Action

Narcotic agonist-analgesic of opiate receptors; inhibits ascending pain pathways; alters pain perception, thus altering response to pain; produces analgesia, respiratory depression, and sedation

Absorption

After patch removal, continued systemic absorption occurs from residual fentanyl in skin, so that serum concentrations fall by average of 50% in ~20-27 hr

Onset: 6 hr

Duration: 72-96 hr

Peak plasma time: 28.8-35.8 hr (dose dependent; following first application)

Peak plasma concentration: 0.38-3.36 ng/mL (dose dependent; following first application)

Distribution

Vd: 4-6 L/kg

Protein binding: 80-85%

Metabolism

Metabolized in liver by CYP3A4

Elimination

Half-life: 20-27 hr

Excretion: Urine (75% mostly as metabolites), feces (9% as metabolites)

What is fentanyl transdermal (skin patch) (duragesic, duragesic-100, duragesic-12, duragesic-25, duragesic-50, duragesic-75)?

Fentanyl is an opioid pain medication. An opioid is sometimes called a narcotic.

The fentanyl skin patch is used to treat moderate to severe chronic pain. Fentanyl is not for treating mild or occasional pain or pain from surgery.

Fentanyl transdermal may also be used for purposes not listed in this medication guide.

What is the most important information i should know about a fentanyl transdermal skin patch?

MISUSE OF THIS MEDICATION CAN CAUSE HARMFUL OR FATAL SIDE EFFECTS.

Do not use this medication unless you are already being treated with a similar opioid (narcotic) pain medicine and your body is tolerant to it. Talk with your doctor if you are not sure you are opioid-tolerant.

Do not expose the skin patch to heat while you are wearing it. This includes a hot tub, heating pad, sauna, or heated water bed. Heat can increase the amount of drug you absorb through your skin and may cause harmful effects.

Fentanyl may be habit forming and should be used only by the person it was prescribed for. Never share fentanyl with another person, especially someone with a history of drug abuse or addiction. Keep the medication in a place where others cannot get to it

Keep both used and unused fentanyl transdermal patches out of the reach of children or pets. The amount of fentanyl in a used skin patch could be fatal to a child or pet who accidentally sucks on or swallows the unit. Seek emergency medical attention if this happens.

Avoid drinking alcohol, or using other medicines that make you sleepy (such as cold medicine, other pain medication, muscle relaxers, and medicine for depression or anxiety). They can add to extreme drowsiness or breathing problems caused by fentanyl.

The fentanyl transdermal patch may burn your skin if you wear the patch during an MRI (magnetic resonance imaging). Remove the patch before undergoing such a test.

Contraindications

Fentanyl Transdermal system is contraindicated in the following patients and situations:

  • in patients who are not opioid-tolerant.
  • in the management of acute or intermittent pain, or in patients who require opioid analgesia for a short period of time.
  • in the management of post-operative pain, including use after out-patient or day surgeries, (e.g., tonsillectomies).
  • in the management of mild pain.
  • in patients with significant respiratory compromise, especially if adequate monitoring and resuscitative equipment are not readily available.
  • in patients who have acute or severe bronchial asthma.
  • in patients who have or are suspected of having paralytic ileus.
  • in patients with known hypersensitivity to fentanyl or any components of the transdermal system. Severe hypersensitivity reactions, including anaphylaxis have been observed with Fentanyl Transdermal system [see Adverse Reactions (6.2)].

Fentanyl Transdermal Description

Fentanyl Transdermal system is a transdermal system containing fentanyl. The chemical name is N-Phenyl-N-(1-(2-phenylethyl)-4-piperidinyl) propanamide. The structural formula is:

The n‑octanol: water partition coefficient is 860:1. The pKa is 8.4.

System Components and Structure

The amount of fentanyl released from each system per hour is proportional to the surface area (25 mcg/hr per 7.8 cm2). The composition per unit area of all system sizes is identical.

Dose*
(mcg/hr)

Size
(cm2)

Fentanyl Content
(mg)

Color of Printing on Back of Patch

12†

3.9

1.375

Dark Blue

25

7.8

2.75

Red

50

15.6

5.50

Green

75

23.4

8.25

Blue

100

31.2

11.0

Gray

*Nominal delivery rate per hour
†Nominal delivery rate is 12.5 mcg/hr

Fentanyl Transdermal system is a rectangular transparent unit comprising a protective liner and four functional layers. Proceeding from the outer surface toward the surface adhering to skin, these layers are:

1)   a backing layer of PET foil;
2)   a drug containing layer of fentanyl and dipropylene glycol with hydroxypropyl cellulose;
3)   an ethylene vinyl-acetate copolymer membrane that controls the rate of fentanyl delivery to the skin surface; and
4)   a silicone adhesive. Before use, a protective liner covering the adhesive layer is removed and discarded.

Non-clinical toxicology

Carcinogenesis, Mutagenesis, and Impairment of Fertility

Carcinogenesis

In a two-year carcinogenicity study conducted in rats, fentanyl was not associated with an increased incidence of tumors at subcutaneous doses up to 33 μg/kg/day in males or 100 μg/kg/day in females (0.16 and 0.39 times the human daily exposure obtained via the 100 mcg/hr patch based on AUC0-24h comparison).

Mutagenesis

There was no evidence of mutagenicity in the Ames Salmonella mutagenicity assay, the primary rat hepatocyte unscheduled DNA synthesis assay, the BALB/c 3T3 transformation test, and the human lymphocyte and CHO chromosomal aberration in-vitro assays.

Impairment of Fertility

The potential effects of fentanyl on male and female fertility were examined in the rat model via two separate experiments. In the male fertility study, male rats were treated with fentanyl (0, 0.025, 0.1 or 0.4 mg/kg/day) via continuous intravenous infusion for
28 days prior to mating; female rats were not treated. In the female fertility study, female rats were treated with fentanyl (0, 0.025, 0.1 or 0.4 mg/kg/day) via continuous intravenous infusion for 14 days prior to mating until day 16 of pregnancy; male rats were not treated. Analysis of fertility parameters in both studies indicated that an intravenous dose of fentanyl up to 0.4 mg/kg/day to either the male or the female alone produced no effects on fertility (this dose is approximately 1.6 times the daily human dose administered by a 100 mcg/hr patch on a mg/m2 basis). In a separate study, a single daily bolus dose of fentanyl was shown to impair fertility in rats when given in intravenous doses of 0.3 times the human dose for a period of 12 days.

PRINCIPAL DISPLAY PANEL - 25 mcg/hr

NDC 0406-9025-76
Five (25 mcg/hr) Systems
Fentanyl Transdermal SYSTEM
25mcg/hr
Rx only
CII

In vivo delivery of 25 mcg/hr fentanyl for 72 hours

Because it can cause trouble breathing which can be fatal,
DO NOT USE Fentanyl Transdermal SYSTEM:

  • For short term or any post-operative pain, or occasional pain
  • For mild pain or pain that can be treated with non-opioid or as-needed opioid medication
  • Unless you have been using other narcotic opioid medicines (must be opioid-tolerant)

Each transdermal system contains: 2.75mg fentanyl
DO NOT USE IF SEAL ON POUCH IS BROKEN
KEEP OUT OF REACH OF CHILDREN
Read enclosed Fentanyl Transdermal system Medication Guide for important safety information.

PHARMACIST: Dispense the Medication Guide provided separately to each patient.
ONLY for pain requiring opioid medicine around-the-clock

Mallinckrodt™

0003894

Rev 01/2016

(web3)